South Carolina Retina Institute (SCRI) can offer patients the latest advancement in the treatment of retinal vein occlusion (RVO) – the FDA-approved Genentech’s VABYSMO® (faricimab-svoa).
We focus on helping our patients retain their vision.
South Carolina Retina Institute (SCRI) can offer patients the latest advancement in the treatment of retinal vein occlusion (RVO) – the FDA-approved Genentech’s VABYSMO® (faricimab-svoa).